Beat The Denominator

Investors should prioritize Bitcoin (BTC) as the ultimate benchmark for capital, treating its historical annual returns as the "risk-free rate" and avoiding any assets that cannot outperform it. High-performance computing remains a high-conviction sector, with NVIDIA (NVDA) and memory manufacturers benefiting from the endless demand for AI-driven intelligence. For long-term exposure to the next computing frontier, Google (GOOGL) is positioned as a primary leader in the emerging field of Quantum Computing. The longevity and healthcare revolution offers immediate opportunities in AI-driven drug discovery and personalized health platforms like Hims & Hers (HIMS). Finally, monitor SpaceX for a potential future IPO, which will likely signal the start of a massive investment cycle in space manufacturing and asteroid mining.

Investors should consider Hims & Hers Health (HIMS) as a primary play in the direct-to-consumer health space, particularly as it transitions into a leader in the peptide and GLP-1 weight-loss market. Following the acquisition of CS Bio manufacturing assets, the company is vertically integrated to produce proprietary oral peptide pills, which could disrupt the injectable drug market by 2026. While the stock is currently experiencing high volatility due to a short squeeze, any pullbacks toward the $15 level should be viewed as a significant entry point based on fundamental value. Watch for regulatory catalysts regarding Testosterone Replacement Therapy (TRT), as expanded FDA labeling for "low libido" would allow HIMS to aggressively cross-sell to its massive existing customer base. Maintain a long-term perspective on the Weight Loss & Longevity sector, favoring companies like HIMS that bypass traditional insurance "denials" through a subscription-based model.

Investors seeking long-term wealth preservation should prioritize Bitcoin (BTC) as a "hard money" asset, targeting an estimated 29% annualized return over the next two decades. For those requiring stability and income, MicroStrategy Preferred Equity (STRC) offers an 11.5% yield and remains fully collateralized even if BTC prices drop by 75%. High-risk investors can gain leveraged exposure to BTC accumulation through MicroStrategy (MSTR), though they must be prepared for extreme price swings and "brutal" drawdowns. In the healthcare sector, Hims & Hers Health (HIMS) remains a high-conviction play on tech disruption, with the recent approval of peptides serving as a significant growth catalyst. To mitigate "bail-in" risks associated with traditional banking, move capital exceeding FDIC limits out of cash and into "thermodynamically sound" digital assets or prediction markets.

Investors should consider Hims & Hers Health (HIMS) as it transitions from a telehealth platform to a legitimate leader in the high-growth peptide market. The company’s acquisition of a specialized manufacturing facility allows it to scale production of treatments for longevity, recovery, and weight loss while adhering to new FDA safety standards. By legitimizing the "gray market" for substances like BPC-157, HIMS is positioned to capture a massive wave of consumers seeking trusted, US-based sources. The development of "painless needle" technology through their Thrive acquisition further lowers the barrier for entry into injectable therapies. With a shift toward partnering with big pharma giants like Novo Nordisk, the stock presents a strong growth opportunity with potential for a short squeeze as these integrations accelerate.

Investors should consider MicroStrategy (MSTR) as a high-conviction proxy for Bitcoin (BTC), as the stock continues to significantly outperform the underlying digital asset. Current price action suggests the company is actively utilizing its At-The-Market (ATM) equity program, creating a strategic entry point for investors before potential selling pressure subsides. Accumulating shares near the $143 level allows investors to capitalize on Michael Saylor’s strategy of "ATMing into strength" to increase the company's BTC holdings. Treat MSTR not as a traditional software company, but as a specialized fundraising vehicle designed to capture maximum upside from a transitioning Bitcoin-based financial system. Monitor the stock's premium to its BTC holdings closely, as it remains the primary institutional instrument for leveraged exposure to the crypto market.

Consider buying Oscar Health (OSCAR), which is currently undervalued with a Rule of 40 score of 63 and significant insider buying from the CEO at the $12.00 level. Hims & Hers Health (HIMS) offers a high-conviction play in personalized medicine, leveraging AI to disrupt traditional pharmacy models while maintaining strong growth and profitability metrics. For exposure to a real estate recovery, The Real Brokerage (REAX) is a top pick that is aggressively gaining market share from traditional brokers and is poised to surge if mortgage rates retreat toward 5%. Investors seeking high yield and dominant market positioning should look at Kaspi.kz (KSPI), a regional "super app" with a massive 89 Rule of 40 score and a dividend yield near 9.5%. Focus on these hyper-growth disruptors during market "flash sales" to capture high-quality assets at a significant discount relative to their gross profit growth.

Maintain a long-term core position in Bitcoin (BTC) despite volatility, as institutional absorption from entities like MicroStrategy supports a trajectory toward a long-term $1 million price target. For investors seeking higher beta, MSTR continues to outperform BTC daily, acting as a high-growth "rocket" for the current cycle. Consider the STRC instrument for a more stable 7%–11.5% yield, which offers significant tax-deferral benefits for retirees and residents of high-tax states. Diversify into high-growth Layer 1 blockchains like Solana (SOL) and Hyperliquid (HYPE), which utilize aggressive token-burn mechanisms similar to corporate share buybacks to drive value. Prepare for periodic 40-50% market drawdowns by ignoring short-term "tweet risk" and focusing on the macro tailwinds of regulatory clarity and global GDP growth.

Investors should prioritize Hims & Hers Health (HIMS) and Oscar Health (OSCR) as defensive growth plays, as both remain "dirt cheap" with valuations decoupled from geopolitical risks. Nebius Group (NBIS) is a high-conviction hyper-growth opportunity, currently reacting to a massive $40 billion backlog and projected for 600% growth over the next year. In the software space, Zeta Global (ZETA) stands out as a rare value play trading significantly below the sector average valuation. SoFi Technologies (SOFI) and Bitcoin miners like CleanSpark (CLSK) are currently moving as high-beta growth assets, offering recovery potential after irrational market sell-offs. Avoid using margin or leveraged ETFs due to high volatility, and consider rotating capital out of "old money" stocks like Walmart and AT&T into these undervalued hyper-growth names.

Investors should consider MicroStrategy (MSTR) as a "catch-up" trade, as the stock has recently underperformed Bitcoin (BTC) despite the company’s massive new acquisition of 13,900 BTC. The company is targeting a 15-20% BTC Yield by 2026, making the stock a high-conviction play for those seeking leveraged exposure to Bitcoin without immediate shareholder dilution. For retail investors, the upcoming availability of MetaPlanet (METP) on Robinhood presents a new opportunity to capitalize on the "MicroStrategy of Japan" narrative and increased liquidity flows. Traders should monitor the STRC digital credit product around its April 15 ex-dividend date to see if the price recovers quickly to its $100 par value after dividend scalping. While Bitcoin remains subject to weekend volatility and "artificial" price drops due to its 24/7 liquidity, institutional accumulation continues to provide a long-term floor for the asset.

Investors seeking high-conviction exposure to Anthropic’s explosive revenue growth should look to Zoom Video Communications (ZM) as the primary "pure play" vehicle.

At a projected $500 billion valuation for Anthropic, Zoom’s estimated 1.2% stake is worth roughly $6 billion, representing a massive 26% of its total market cap.

Zoom offers significant downside protection due to its $7.8 billion cash reserve and zero debt, effectively allowing investors to buy the core business at a deep-value valuation of 7.5x EBITDA.

For more diversified exposure, Amazon (AMZN) holds a massive 19% stake in Anthropic worth approximately $95 billion, though it represents a smaller 3.8% portion of its overall market cap.

Avoid Microsoft (MSFT) for this specific theme, as its 1.4% stake in Anthropic is negligible compared to its heavy concentration in OpenAI.

Investors should monitor MicroStrategy (MSTR) for an imminent 8-K filing, as the company is expected to announce a massive Bitcoin (BTC) purchase of up to 30,000 coins. While BTC remains a long-term hold, be prepared for heightened weekend volatility where it often acts as a "liquidity valve" for global macro shocks while traditional markets are closed. For those seeking a defensive alternative to volatile stocks, Stretch (STRC) is positioned as a "safe haven" engineered product designed to trade near the $100 level. A critical trading window for STRC occurs around the 15th, providing an opportunity to observe how quickly the price recovers after going ex-dividend. Given the current "Macro Madness" and geopolitical uncertainty, maintaining higher cash levels and focusing on a 2030s time horizon is recommended to avoid being shaken out by short-term market noise.

Investors should view MicroStrategy (MSTR) as a "Bitcoin weighing machine" rather than a speculative proxy, focusing on its 14% increase in Bitcoin-per-share value rather than short-term price premiums. With the mNAV multiple compressing toward 1.0x, the stock offers a more predictable entry point for long-term holders seeking exposure to the company's aggressive BTC Yield strategy. For income-focused investors, the preferred stock STRC presents a high-liquidity opportunity with a strong credit rating of 4.4x backing the debt. Pay close attention to STRC as it goes ex-dividend on April 15, watching for the price to quickly recover to its $100 par value. As Bitcoin (BTC) stabilizes around $73,000 with neutral market sentiment, these instruments provide a structured way to play the asset's macro resilience.

Investors should consider Hims & Hers Health (HIMS) as a high-conviction buy under $20, as the market has yet to price in an estimated $210 million in annual recurring revenue from its new weight loss subscriptions. Nebius Group (NBIS) remains a top pick in the AI infrastructure space following a massive $27 billion compute deal with Meta (META), signaling its evolution into a specialized "GPU Cloud" powerhouse. While Iris Energy (IREN) is currently trading at a 55% discount from recent highs, investors should be cautious of potential share dilution from its $6 billion equity offering. For those seeking exposure to the AI boom, prioritize companies like NBIS that use convertible debt to fund data centers rather than dilutive "At-The-Market" stock sales. Overall, the "GPU Cloud" sector offers significant upside as global demand for AI compute capacity continues to outpace current supply.

Bitcoin (BTC) currently appears undervalued at $72,500, as neutral sentiment levels historically align with a price target closer to $95,000. Investors should monitor the iShares Bitcoin Trust (IBIT) for institutional price action and use the next two weeks to confirm if the current "risk-on" trend is sustainable. MicroStrategy (MSTR) remains a high-conviction leveraged play on BTC, though investors must account for potential equity dilution as the company aggressively sells shares to fund more coin purchases. A major upcoming catalyst is the expected announcement of massive BTC acquisitions—estimated between 5,700 and 10,000 coins—funded by the issuance of STRC preferred stock. For those seeking stability with crypto exposure, STRC is emerging as a "TradFi stablecoin" that provides a low-volatility way to benefit from MicroStrategy’s institutional credit and BTC holdings.

Accumulate Bitcoin (BTC) as it nears the $72,000 level, supported by institutional catalysts like Morgan Stanley’s new trust and its role as a leading indicator for tech recoveries. For a higher-risk, leveraged play on crypto, monitor MicroStrategy (MSTR), but be mindful that ongoing share offerings may temporarily suppress its price relative to BTC. Investors seeking passive income should consider STRC, which offers an 11.5% yield backed by Bitcoin, though you must watch for price "de-pegs" below 100 during ex-dividend dates. Given that oil prices between $90–$97 and geopolitical tensions are creating market volatility, use the current "green bounce" to trim risky growth stocks and increase your cash holdings. Avoid chasing short-term rallies in the broader market, as price action is currently driven by unpredictable headlines rather than long-term fundamentals.

Accumulate Tesla (TSLA) during its current 30% drawdown to capitalize on long-term catalysts like Full Self-Driving (FSD) and the Robotaxi launch. Use TSLA as a strategic macro hedge against rising energy costs, as it remains the dominant player capable of providing a 10x fuel economy advantage if oil spikes to $150. For income-focused investors seeking stability, the "Stretch" instrument related to MicroStrategy (MSTR) offers an 11.5% tax-deferred yield with minimal volatility. Avoid over-trading volatile mid-caps like Hims & Hers Health (HIMS) or reacting to regulatory news in UnitedHealth Group (UNH), as current market mechanics often ignore fundamental "wins." Maintain a long-term investment horizon toward 2030 and consider holding cash to buffer against "tweet-based" market irrationality and unpredictable price swings.

Institutional demand is currently absorbing over twice the daily mined supply of Bitcoin (BTC), creating a supply shock that supports a bullish outlook as it holds above the $70,000 level. Investors seeking amplified returns should look to MicroStrategy (MSTR), which is currently providing roughly 1.5x leveraged exposure to Bitcoin's price movements. For those prioritizing stability and income, the STRC "Centi-Stablecoin" offers a high-yield TradFi bridge with an 11.5% yield and a stable peg near $100. International investors can access these institutional-grade yields through DeFi protocols like APYX, which bypasses the need for traditional U.S. brokerage accounts. Monitor the Crypto Fear and Greed Index as it shifts toward "neutral," as this transition often signals the start of a broader market rally.

Investors should consider Hims & Hers Health, Inc. (HIMS) as it disrupts the healthcare sector by offering GLP-1 weight loss treatments at a highly competitive $149/month price point. The company is transitioning from a reactive pharmacy to a proactive Longevity platform, with a high-conviction shift toward Peptides as the next major growth driver for health optimization. By bypassing legacy systems like Epic and building proprietary digital health records, HIMS is creating a significant "software moat" among younger, digital-first consumers. Management is utilizing AI-driven marketing on platforms like Meta and Google to lower acquisition costs while maintaining high customer retention through life-long treatment plans. This "10x cheaper" model positions HIMS as a dominant drug distribution channel that challenges big pharma incumbents like Novo Nordisk and LabCorp.

Accumulate Bitcoin (BTC) during this consolidation phase near $70,000, as current "Fear" sentiment levels suggest the asset is undervalued relative to its long-term potential. Monitor MicroStrategy (MSTR) common stock for a potential buying opportunity, as it has recently decoupled from Bitcoin and is trading at a significant discount due to market volatility. Institutional investors should focus on Digital Credit and preferred equity instruments, which are currently seeing 2.5x higher demand than traditional common stock offerings. Watch for a shift in capital flows toward "hard assets" as geopolitical tensions subside, which could trigger a major revaluation of the crypto market. Pay attention to companies utilizing AI-driven financial advertising to reach traditional investors, as this technology is becoming a key driver for corporate capital raises and investor acquisition.

Investors should maintain a bearish outlook on the cybersecurity sector due to extreme overvaluations and poor Rule of 40 scores across the industry. Avoid high-multiple "darlings" like CrowdStrike (CRWD) and Cloudflare (NET), as their current revenue multiples of 16x and 26x respectively are not supported by their 20-22% growth rates. Sell or avoid Clear Secure (YOU), as its recent 50% price surge is considered a narrative-driven spike that is unlikely to be sustained. Instead of pure-play cyber stocks, pivot capital toward "Hyperscalers" like NVIDIA (NVDA), Microsoft (MSFT), and Meta (META), which offer superior profit margins and better growth-to-value ratios. Be prepared for a potential 50-70% valuation correction in the cybersecurity space to bring these stocks in line with broader high-growth tech fundamentals.